We analyzed HIF2α expression in a tissue microarray including 150 ccRCC tissues and 30 adjacent normal tissues by immunohistochemistry (Supplementary Fig. S2E) (Supplementary Table S1A) and found that the HIF2α-positive group showed significantly poorer overall survival than the HIF2α-negative group (Fig. S2F) (Supplementary Table S1A), indicating that HIF2α may be a potentially valuable biomarker for the prognosis of ccRCC. This evidence concerns the gene EPAS1 and nonpapillary renal cell carcinoma.